PharmaEssentia Corp (藥華醫藥) yesterday said that it has applied for marketing approval for its ropeginterferon alfa-2b drug with the China National Medical Products Administration.
The company seeks approval to use the treatment for a rare type of blood cancer, polycythemia vera, it said in a regulatory filing.
The interferon drug, sold in the US under the name Besremi, is the only approved first-line treatment for polycythemia vera, with its sole competitor being the US-based Incyte Corp’s Jakafi, which has been approved as second-line treatment.
Photo: Reuters
The drug has gained approval to be used in the treatment of adult polycythemia vera patients in Taiwan, Switzerland, Israel, South Korea, the US and the EU.
The company in October said that it was targeting China and Japan as the drug’s next markets.
PharmaEssentia did not specify the estimated date of completion for the marketing application, saying in the filing that it is subject to the Chinese agency’s procedures for case acceptance.
There are about 400,000 polycythemia vera patients in China, the company added.
Polycythemia vera is a chronic, progressive myeloproliferative neoplasm, and it is primarily characterized by a high count of red blood cells, PharmaEssentia said.
The blood disorder could result in cardiovascular complications, such as thrombosis and embolism, and often develops into secondary myelofibrosis or leukemia, it said.
Besremi is PharmaEssentia’s most significant product, helping boost its revenue 383.44 percent year-on-year to NT$2.63 billion (US$85.65 million) in the first 11 months of last year, company data showed.
The company reported a net loss of NT$1.22 billion in the first three quarters of last year, due to higher marketing, management, and research and development costs.
That translated into losses per share of NT$4.37, company data showed.
Analysts said the new drug would lead to robust sales growth and operating leverage in the long term.
The company is also conducting a phase 3 clinical trial for the drug to treat essential thrombocythemia, a rare disorder in which the bone marrow produces too many platelets.
PharmaEssentia yesterday in a separate filing said that it has received positive opinions from the Data and Safety Monitoring Board for the trial.
The board comprises independent experts who review clinical study data for new drugs.
It confirmed the safety of the trial and recommended that the firm continue conducting it according to protocols, PharmaEssentia said.
Essential thrombocythemia is a myeloproliferative neoplasm characterized by an overproduction of platelets in the blood resulting from a genetic mutation.
The number of people with essential thrombocythemia is similar to those with polycythemia vera, the company said.
PharmaEssentia has registered 90 percent enrollment for the trial and plans to complete it as soon as possible, it added.
The company’s shares rose 62.8 percent last year, closing at NT$477 on Friday in Taipei trading.
The stock last month joined MSCI Global Standard Indices after it made considerable gains last year, global index provider MSCI Inc has said.
Leading Taiwanese bicycle brands Giant Manufacturing Co (巨大機械) and Merida Industry Co (美利達工業) on Sunday said that they have adopted measures to mitigate the impact of the tariff policies of US President Donald Trump’s administration. The US announced at the beginning of this month that it would impose a 20 percent tariff on imported goods made in Taiwan, effective on Thursday last week. The tariff would be added to other pre-existing most-favored-nation duties and industry-specific trade remedy levy, which would bring the overall tariff on Taiwan-made bicycles to between 25.5 percent and 31 percent. However, Giant did not seem too perturbed by the
AI SERVER DEMAND: ‘Overall industry demand continues to outpace supply and we are expanding capacity to meet it,’ the company’s chief executive officer said Hon Hai Precision Industry Co (鴻海精密) yesterday reported that net profit last quarter rose 27 percent from the same quarter last year on the back of demand for cloud services and high-performance computing products. Net profit surged to NT$44.36 billion (US$1.48 billion) from NT$35.04 billion a year earlier. On a quarterly basis, net profit grew 5 percent from NT$42.1 billion. Earnings per share expanded to NT$3.19 from NT$2.53 a year earlier and NT$3.03 in the first quarter. However, a sharp appreciation of the New Taiwan dollar since early May has weighed on the company’s performance, Hon Hai chief financial officer David Huang (黃德才)
NVIDIA FACTOR: Shipments of AI servers powered by GB300 chips would undergo pilot runs this quarter, with small shipments possibly starting next quarter, it said Quanta Computer Inc (廣達), which supplies artificial intelligence (AI) servers powered by Nvidia Corp chips, yesterday said that AI servers are on track to account for 70 percent of its total server revenue this year, thanks to improved yield rates and a better learning curve for Nvidia’s GB300 chip-based servers. AI servers accounted for more than 60 percent of its total server revenue in the first half of this year, Quanta chief financial officer Elton Yang (楊俊烈) told an online conference. The company’s latest production learning curve of the AI servers powered by Nvidia’s GB200 chips has improved after overcoming key component
UNPRECEDENTED DEAL: The arrangement which also includes AMD risks invalidating the national security rationale for US export controls, an expert said Nvidia Corp and Advanced Micro Devices Inc (AMD) have agreed to pay 15 percent of their revenue from Chinese artificial intelligence (AI) chip sales to the US government in a deal to secure export licenses, an unusual arrangement that might unnerve both US companies and Beijing. Nvidia plans to share 15 percent of the revenue from sales of its H20 AI accelerator in China, a person familiar with the matter said. AMD is to deliver the same share from MI308 revenue, the person added, asking for anonymity to discuss internal deliberations. The arrangement reflects US President Donald Trump’s consistent effort to engineer
RSS